Vectura partners with Monash University to support development of inhaled oxytocin to prevent postpartum haemorrhage

  • Date 15 Sep 2020

Vectura announces that it has signed an agreement with Monash University’s Institute of Pharmaceutical Sciences (MIPS), to develop inhaled oxytocin delivered via a dry powder inhaler to prevent postpartum haemorrhage (PPH) in childbirth.

An inhaled formulation of oxytocin, currently administered via injection, is expected to provide important advantages including ease of use, rapid onset of action and safe storage outside of the cold chain. Vectura will receive undisclosed revenues on a fee-for-service basis.

Read more

Join an ambitious, supportive community of world-class scientists, engineers and entrepreneurs

Read more